Solta Medical's novel addition to its aesthetic device solutions, the Clear + Brilliant pélo™ laser, offers personalized results with groundbreaking laser hair removal [LHR] technology to make it fast and simple with minimal pain for anyone to get rid of unwanted hair.
The Clear + Brilliant pélo™ laser provides a highly effective treatment in a short amount of time due to its innovative linear scanning technology and the largest treatment window in the market. A full back takes only 8-12 minutes, and full legs take about 36 minutes. After 5-6 treatments, patients can see the results they want, and still have money in their pocket for the long run.
Each treatment can be customized depending on the individual's needs, and patient comfort is enhanced by minimizing pain on contact through a sapphire glass handpiece that quickly chills to 0°C. So patients and physicians can rest easy that their individual needs are met.
To view the multimedia release go to:
http://www.multivu.com/players/English/7621831-clear-brilliant-pelo-laser-hair-removal/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
A sexy teen novel debut Casey by Marx.
A fresh story about Cody Reese, the skateboarding drug dealer who want it all. No time to grow up, but stay up, partying a night on the beaches of Santa Barbara, California AKA Paradise.
360 to Paradise has all the gritty action you can hope for.
Let a skateboarding, drug dealing graffiti artist who reps for the Montecito Rats take you on a wild ride in one day of his life in Santa Barbara.
Buy the acclaimed fiction novel here: https://www.amazon.com/360-Paradise-Casey-Marx-ebook/dp/B01LBFEMQ0
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
New release on Amazon, Chased into his Destiny, new Best Seller, Best Selling African Novel, African Best Seller Series, new African Author, best seller
